Home Cart Sign in  
Chemical Structure| 61281-38-7 Chemical Structure| 61281-38-7
Chemical Structure| 61281-38-7
Product Citations

Alternative Products

Product Details of Schisandrin A

CAS No. :61281-38-7
Formula : C24H32O6
M.W : 416.51
SMILES Code : C[C@H]1CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C[C@H]1C
Synonyms :
Schizandrin-A; Wuweizisu-A; Deoxyschisandrin
MDL No. :MFCD09026934
InChI Key :JEJFTTRHGBKKEI-OKILXGFUSA-N
Pubchem ID :155256

Safety of Schisandrin A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
BEAS‑2B 0, 25, 50, 75, 100 µM 24 h SchA significantly reduced the viability of BEAS‑2B cells in a concentration-dependent manner, indicating its cytotoxicity against normal lung epithelial cells. PMC8522958
H1299 0, 25, 50, 75, 100 µM 24 h SchA significantly reduced the viability of H1299 cells in a concentration-dependent manner, indicating its cytotoxicity against NSCLC cells. PMC8522958
H1975 0, 25, 50, 75, 100 µM 24 h SchA significantly reduced the viability of H1975 cells in a concentration-dependent manner, indicating its cytotoxicity against NSCLC cells. PMC8522958
A549 0, 25, 50, 75, 100 µM 24 h SchA significantly reduced the viability of A549 cells in a concentration-dependent manner, indicating its cytotoxicity against NSCLC cells. PMC8522958
Spd2 cells 5, 10, 20 μM 48 h To study the effect of Schisandrin A on the vitality of Spd2 cells, the results showed that Schisandrin A significantly improved cell viability PMC10326307
Bone Marrow Macrophages (BMMs) 0, 50, 100, 200 μM 7 days Schisandrin A inhibited RANKL-induced osteoclastogenesis in a dose-dependent manner and significantly inhibited F-actin ring formation and osteoclast resorptive function at 200 μM. PMC7574870
Bone Marrow Macrophages (BMMs) 200 μM 2 days Schisandrin A at 200 μM did not induce apoptosis of BMMs and did not induce apoptosis of mature osteoclasts when co-cultured with M-CSF and RANKL for 2 days. PMC7574870
C2C12 myotubes 20 μM 12 h SNA treatment increased protein synthesis and enhanced the expression of pAkt, pFoxO, and p70S6K. PMC7282012
C2C12 myotubes 10 μM 12 h SNA treatment significantly inhibited the expression of muscle degradation factors (myostatin, atrogin1, and MuRF1) induced by DEX. PMC7282012
Rat ovarian granulosa cells 0, 1.25, 2.5, 5, 10, 20 µM 24 h To investigate the effects of Schisandrin on the viability of rat ovarian granulosa cells, the results showed that Schisandrin had no significant cytotoxic effect on rat ovarian granulosa cells within the concentration range PMC11773789
KGN cells 0, 1.25, 2.5, 5, 10, 20 µM 24 h To investigate the effects of Schisandrin on the viability of KGN cells, the results showed that Schisandrin had no significant cytotoxic effect on KGN cells within the concentration range PMC11773789
Human iPSCs-derived neurons 10 µM and 100 µM 20 min Schisandrin A significantly inhibited spontaneous discharges and 4-AP-induced discharges of iPSCs-derived neurons at both 10 µM and 100 µM. PMC11464642

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
C57BL/6 mice Ovariectomy-induced osteoporosis model Intraperitoneal injection 100 mg/kg Every other day for 6 weeks Schisandrin A significantly decreased ovariectomy-induced bone loss and suppressed osteoclastogenesis by inhibiting ROS and enhancing the expression of Nrf2. PMC7574870
C57BL/6 male mice Dexamethasone-induced muscle atrophy model Oral 20 mg/kg Once daily for 10 days SNA treatment significantly increased muscle weight and grip strength, and reduced the expression of muscle degradation factors. PMC7282012
Chickens E. coli infection model Intraperitoneal injection 50 mg/kg, 100 mg/kg, 200 mg/kg Once daily for 5 days To evaluate the therapeutic efficacy of Schisandrin A on E. coli infection in chickens, results showed that medium and high doses of Schisandrin A significantly improved weight gain, reduced liver index and serum ALT, AST enzyme activity, decreased concentrations of inflammatory markers and LPS, and increased the expression of tight junction proteins. PMC8417393
SD rats Type 2 diabetic rat model Oral 50 mg/kg Once daily for 4 weeks Schisandrin A has a protective effect on diabetic nephropathy in rats, EGFR may be a potential therapeutic target, and AKT/GSK-3β may be involved in this process. PMC11351691

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.00mL

2.40mL

1.20mL

24.01mL

4.80mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Wang CP, Li GC, et al. Neuroprotective effect of schizandrin A on oxygen and glucose deprivation/reperfusion-induced cell injury in primary culture of rat cortical neurons. J Physiol Biochem. 2014 Sep;70(3):735-47.

[2]Liang XX, Liu GT, et al. Synthesis and MDR inhibitory activity evaluation of derivatives of schizandrin A. J Asian Nat Prod Res. 2010 Jul;12(7):549-56.

[3]Li WL, Xin HW, Su MW, Xiong L. Inhibitory effects of schisandrin A and schisandrin B on CYP3A activity. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):163-9

[4]Li WL, Xin HW, Su MW. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):187-92

[5]Xu D, Liu J, Ma H, Guo W, Wang J, Kan X, Li Y, Gong Q, Cao Y, Cheng J, Fu S. Schisandrin A protects against lipopolysaccharide-induced mastitis through activating Nrf2 signaling pathway and inducing autophagy. Int Immunopharmacol. 2020 Jan;78:105983

[6]Tu C, Huang X, Xiao Y, Song M, Ma Y, Yan J, You H, Wu H. Schisandrin A Inhibits the IL-1β-Induced Inflammation and Cartilage Degradation via Suppression of MAPK and NF-κB Signal Pathways in Rat Chondrocytes. Front Pharmacol. 2019 Jan 29;10:41

[7]Zhi Y, Jin Y, Pan L, Zhang A, Liu F. Schisandrin A ameliorates MPTP-induced Parkinson's disease in a mouse model via regulation of brain autophagy. Arch Pharm Res. 2019 Nov;42(11):1012-1020

[8]Wan MLY, Turner PC, Co VA, Wang MF, Amiri KMA, El-Nezami H. Schisandrin A protects intestinal epithelial cells from deoxynivalenol-induced cytotoxicity, oxidative damage and inflammation. Sci Rep. 2019 Dec 16;9(1):19173

[9]Kwon DH, Cha HJ, Choi EO, Leem SH, Kim GY, Moon SK, Chang YC, Yun SJ, Hwang HJ, Kim BW, Kim WJ, Choi YH. Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling. Int J Mol Med. 2018 Jan;41(1):264-274

 

Historical Records

Categories